Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Cell Infect Microbiol ; 14: 1407246, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38962322

RESUMO

Introduction: In the battle against multidrug-resistant bacterial infections, ceftazidime- avibactam (CZA) stands as a pivotal defense, particularly against carbapenemresistant (CR) Gram-negative pathogens. However, the rise in resistance against this drug poses a significant threat to its effectiveness, highlighting the critical need for in-depth studies about its resistance mechanisms. Methods: This research focuses on the genomic characterization of CR- and CZA-resistant Escherichia coli (n=26) and Klebsiella pneumoniae (n=34) strains, harboring the blaNDM and/or blaOXA-48-like genes, at a major Lebanese tertiary care medical center, using whole genome sequencing (WGS). Results: Our findings revealed a notable prevalence of blaNDM in all K. pneumoniae strains isolates, with 27 of these also harboring blaOXA-48. On the other hand, E. coli strains predominantly carried the blaNDM-5 gene. Whole genome sequencing (WGS) identified a predominance of ST383 among K. pneumoniae strains, which possessed a multi-replicon IncFIB-IncHI1B plasmid harboring the blaNDM-5. Additionally, various Inc group plasmids in K. pneumoniae across multiple sequence types were found to carry the blaNDM. Similarly, diverse STs of E. coli were observed to carry blaNDM-5 on different plasmids. Discussion: The study underscores NDM carbapenemases as a paramount resistance mechanism in Lebanon,jeopardizing critical last-resort treatments. It also illuminates the role of varied sequence types and mobile genetic elements in the spread of NDM resistance,stressing the urgent need for strategies to mitigate this threat, especially in nosocomial infections.


Assuntos
Antibacterianos , Compostos Azabicíclicos , Carbapenêmicos , Ceftazidima , Combinação de Medicamentos , Farmacorresistência Bacteriana Múltipla , Escherichia coli , Klebsiella pneumoniae , Sequenciamento Completo do Genoma , beta-Lactamases , Ceftazidima/farmacologia , Compostos Azabicíclicos/farmacologia , Humanos , Líbano , beta-Lactamases/genética , beta-Lactamases/metabolismo , Klebsiella pneumoniae/genética , Klebsiella pneumoniae/efeitos dos fármacos , Antibacterianos/farmacologia , Escherichia coli/genética , Escherichia coli/efeitos dos fármacos , Carbapenêmicos/farmacologia , Farmacorresistência Bacteriana Múltipla/genética , Plasmídeos/genética , Testes de Sensibilidade Microbiana , Transferência Genética Horizontal , Genoma Bacteriano , Enterobacteriáceas Resistentes a Carbapenêmicos/genética , Enterobacteriáceas Resistentes a Carbapenêmicos/efeitos dos fármacos , Enterobacteriáceas Resistentes a Carbapenêmicos/isolamento & purificação , Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo , Centros de Atenção Terciária
2.
J Infect Dev Ctries ; 13(7): 612-618, 2019 07 31.
Artigo em Inglês | MEDLINE | ID: mdl-32065818

RESUMO

INTRODUCTION: Infection with non-tuberculosis mycobacteria (NTM) has been on the rise globally causing a wide spectrum of respiratory and extrapulmonary infections in humans. Studies on these pathogens from the Middle-East including Lebanon are scarce. METHODOLOGY: This retrospective study addresses the approach used for investigation, speciation and antimicrobial resistance (AMR) profiles of recovered NTM isolates from respiratory sources at a major tertiary care center in Lebanon during two periods (2003-2007 and 2013-2017). Processing of specimens, culture and differentiation of recovered NTM isolates from Mycobacterium tuberculosis were done in-house according to standard procedures. Upon request, speciation and AMR testing were performed using molecular and broth dilution methods, respectively, at Mayo Medical Laboratories (Rochester, Minnesota, USA). RESULTS: Among 108 NTM analyzed isolates, 8 species were revealed during the two periods: M. simiae (51% vs 61%), M. avium complex (MAC) (6 % vs 12%) M. fortuitum (12% vs 5%), M. gordonae (6% vs 5%), M. abscessus (6% vs 7%), M. immunogenum (12% vs 0%), M. szulgai (4% vs 0%) and M. peregrinum (0% vs 2%). M. simiae isolates showed high susceptibility (93%-96%) to amikacin and clarithromycin, but high resistance to rifampin, ethambutol, ciprofloxacin, rifabutin, linezolid, trimethoprim/sulfamethoxazole and moxifloxacin. MAC isolates were only susceptible to clarithromycin (86%). M. abscessus isolates were uniformly susceptible to amikacin (100%). CONCLUSION: The revelaed different NTM species, with predominance of M.simiae and various AMR profiles provide a current epidemiologic database and help guiding the selection of appropriate empirical therapy once the clinical relevance is established.


Assuntos
Antituberculosos/farmacologia , Farmacorresistência Bacteriana , Infecções por Mycobacterium não Tuberculosas/epidemiologia , Infecções por Mycobacterium não Tuberculosas/microbiologia , Micobactérias não Tuberculosas/isolamento & purificação , Infecções Respiratórias/epidemiologia , Infecções Respiratórias/microbiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Técnicas Bacteriológicas , Feminino , Técnicas de Genotipagem , Humanos , Líbano/epidemiologia , Masculino , Pessoa de Meia-Idade , Micobactérias não Tuberculosas/classificação , Micobactérias não Tuberculosas/efeitos dos fármacos , Prevalência , Estudos Retrospectivos , Centros de Atenção Terciária , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...